GH-35

Primary objective: To evaluate the preliminary effectiveness of GH35 tablets in advanced solid tumors with KRAS G12C mutations, such as non-small cell lung cancer, pancreatic cancer, colorectal cancer, etc. Secondary objectives: 1. To evaluate the safety of GH35 tablets in subjects with advanced solid tumors with KRAS G12C mutations, such as non-small cell lung cancer, pancreatic cancer, colorectal cancer, etc. 2. To evaluate the pharmacokinetic (PK) characteristics of GH35 tablets in subjects with advanced solid tumors with KRAS G12C mutations, such as non-small cell lung cancer, pancreatic cancer, colorectal cancer, etc.